ClinicalTrials.gg
RecruitingNCT07249034BRAVEUpdated Oct 7, 2026

Impact of Epilepsy on the Brainstem Adenosine Pathway and Its Relation With Arousal and Respiratory Reactivity

An interventional study of 1 Hypercapnic challenge while participant is awake and PET/MRI acquisition in Epilepsy, Drug-resistant Focal Epilepsy and Healthy Controls, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 7, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Epilepsy by Hospices Civils de Lyon — 12 open to participants now, 13 under way, none of them phase 3. Epilepsy · Hospices Civils de Lyon.

Planned enrollment
13th of 20
50 · median 70
Started
2026
with 5 others
No phase
16 of 27
7 open now
Primary completion
2028-10
later than 9 of 12 live
Registered
23rd of 27
by date

Among the 27 studies in Epilepsy by Hospices Civils de Lyon, this one is the 13th largest by planned enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2026, is one of 16 with no phase, reaches primary completion later than 9 of the 12 other live ones, and was the 23rd registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

12 of the 27 studies in Epilepsy by Hospices Civils de Lyon are open now, in 2 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Epilepsy by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Despite the continuous development of new antiseizure medications over the past 25 years, 30% of patients with epilepsy suffer from drug-resistant seizures and are at risk of epilepsy-related complications, like cognitive dysfunctions, sleep-disordered breathing or Sudden and Unexpected Death in Epilepsy (SUDEP). SUDEP typically occurs during sleep, after a nocturnal seizure, and primarily results from a postictal central respiratory dysfunction in patients with generalized convulsive seizure (GCS), suggesting that interaction between respiratory dysfunction and sleep state may play a role in its pathophysiology.

Post-mortem data in SUDEP patients showed alteration of neuronal populations involved in respiratory control in the medulla. Accordingly, pharmacologic strategies aimed at reducing the severity of postictal respiratory dysfunction has appeared as one of the most promising way to prevent SUDEP. However, no encouraging result has hitherto been reported.

Interconnections between the complex network that regulates arousal and sleep and the respiratory network are numerous. They primarily include the relation between chemosensitive regulation and arousal system to ensure asphyxia-induced arousal (i.e. arousal to elevated CO2), especially through serotonin (5HT)-dependent connections in brain stem. The link between alterations of the brainstem networks involved in arousal regulation and respiratory dysfunction has not been characterized in patients with epilepsy yet.

Like 5HT, adenosine is deeply implicated in the regulation of sleep and central respiratory control.

Seizures transiently increase adenosine extracellular levels. Adenosine physiological effects in the brain are mediated through the activation of two types of Adenosine receptors (ARs), A1Rs and A2ARs. Extracellular adenosine promotes sleep via A1R-dependant inhibition of glutamatergic neurons in the basal forebrain, but also via A2AR-dependant activation of neurons in the nucleus accumbens. Respiration is also inhibited by A1R and A2AR. Most importantly, it has been shown that drug-resistant epilepsy is associated with long-term alterations of ARs cortical expression. However, whether or not a similar epilepsy-related plasticity of ARs occurs in the brainstem and may participate to chronic arousal and respiratory dysfunction in epilepsy has never been investigated.

Considering the tight interplay between central respiratory control, arousal regulation and brainstem adenosine, the main hypothesis of the BRAVE study is that epilepsy might result in alterations of the distribution of A1Rs in the brainstem structures involved in respiratory regulation and/or arousal control, especially in the brainstem structures involved in respiratory regulation under hypercapnic condition.

The study combines clinical respiratory characterization, morphological, functional and metabolic imaging, using the hybrid simultaneous 3T MRI-PET scanner (Siemens Biograph mMR) of the CERMEP. Combining PET with anatomical and functional MR imaging enables non-invasively in vivo mapping of receptor binding and functional neuronal assessment of a physiological task in the entire brain with high spatial resolution.

Investigators already performed fMRI study of respiratory centers, showing number of functional changes in brainstem regions participating to the central control of respiration, including reduced activation during breath-holding fMRI, in patients with epilepsy. The BRAVE study will use the same respiratory paradigm as the one used in this past study.

PET imaging will be focused on A1R, using [18F]CPFPX, a selective A1R antagonist.

03

Conditions studied

  • Epilepsy
  • Drug-resistant Focal Epilepsy
  • Healthy Controls

Browse trials for

Keywords

  • Epilepsy
  • adenosine pathway
  • respiratory reactivity
  • PET-MRI
  • [18F]CPFPX
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For patients

    1. Written obtained from study subject and ability for study subject to comply with the requirements of the study
    2. Aged 18 to 55 years old
    3. Diagnosis of focal epilepsy or of idiopathic generalized epilepsy, as defined by the International League Against Epilepsy
    4. Diagnosis of epilepsy, as defined by the International League Against Epilepsy as failure of adequate trials of two tolerated, appropriately chosen and used antiseizure drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom
    5. Patients with ≥3 focal to bilateral tonic-clonic seizure (FBTCS) or generalized tonic-clonic seizure (GTCS) during the past 18 months
    6. For women of , use highly effective until the end of relevant systemic exposure (V2)
  • For healthy volunteers

    1. Written informed consent obtained from study subject and ability for study subject to comply with the requirements of the study
    2. Aged 18 to 55 years old
    3. For women of childbearing potential, use highly effective contraception until the end of relevant systemic exposure (V2)

Exclusion criteria

Exclusion Criteria:

  • For patients

    1. Ongoing or chronic respiratory insufficiency defined as breathlessness Grade ≥ 2 using the modified Medical Research Council Dyspnea Scale and/or patient treated by a pneumologist for respiratory insufficiency
    2. Cardiac insufficiency defined as symptoms Grade ≥ 2 using Functional Classification and/or patient treated by a cardiologist for chronic heart failure
    3. Ischaemic heart disease defined as history of myocardial ischemia and/or of typical angina confirmed by a cardiologist.
    4. Obstructive sleep-apnea syndrome, defined as participant who had been diagnosed for Obstructive sleep apnoea by polysomnography, whether a dedicated therapy is ongoing or not
    5. Ongoing treatment with selective serotonin reuptake inhibitor (Selective Serotonin Reuptake Inhibitors): Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors): Duloxetine, Milnacipran, Venlafaxine
    6. Hypercapnic challenges (History of stroke in the last 5 years, space-occupying lesion in the brain associated with brain oedema and/or mass effect on MRI/CT scan)
    7. MRI contra-indication (presence of metallic elements, claustrophobia)
    8. Patient treated with vagal nerve stimulation or deep brain stimulation
    9. Pregnant women, women in labor or breastfeeding women, based on declarations at V0
    10. Patients suffering from a psychiatric disorder, regardless of its etiology, whose care is provided under compulsory measures
    11. Persons deprived of their liberty by a judicial or administrative decision
    12. Adults subject to a legal protection measure (guardianship, curatorship)
    13. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
    14. Positive urine pregnancy test at V2, if applicable
    15. to [18F]-CPFPX
  • For healthy volunteers

    1. History of epilepsy
    2. Ongoing or chronic respiratory insufficiency defined as breathlessness Grade ≥ 2 using the modified Medical Research Council Dyspnea Scale and/or patient treated by a pneumologist for respiratory insufficiency
    3. Cardiac insufficiency defined as symptoms Grade ≥ 2 using New York Heart Association Functional Classification and/or patient treated by a cardiologist for chronic heart failure
    4. Ischaemic heart disease defined as history of myocardial ischemia and/or of typical angina confirmed by a cardiologist.
    5. Obstructive sleep-apnea syndrome, defined as participant who had been diagnosed for Obstructive sleep apnoea by polysomnography, whether a dedicated therapy is ongoing or not
    6. Ongoing treatment with selective serotonin reuptake inhibitor : SSRIs (Selective Serotonin Reuptake Inhibitors) : Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) : Duloxetine, Milnacipran, Venlafaxine
    7. Hypercapnic challenges contra-indication (History of stroke in the last 5 years, space-occupying lesion in the brain associated with brain oedema and/or mass effect on MRI/CT scan)
    8. MRI contra-indication (presence of metallic elements, claustrophobia)
    9. Pregnant women, women in labor or breastfeeding women, based on declarations at V0
    10. Patients suffering from a psychiatric disorder, regardless of its etiology, whose care is provided under compulsory measures
    11. Persons deprived of their liberty by a judicial or administrative decision
    12. Adults subject to a legal protection measure (guardianship, curatorship)
    13. Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
    14. Positive urine pregnancy test at V2, if applicable
    15. Hypersensitivity to [18F]-CPFPX
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Patients with drug-resistant epilepsy

    Diagnosis of refractory focal epilepsy or of refractory idiopathic generalized epilepsy, as defined by the International League Against Epilepsy. The following procedures will be carried out as part of the research: * Hypercapnic challenge * PET/MRI acquisition with \[18F\]-CPFPX Baseline (0-70 min) Hypercapnic challenge (Breath holding) (70-100 min) Return to equilibrium (100-120 min)

    Procedure: 1 Hypercapnic challenge while participant is awake · Procedure: PET/MRI acquisition

  • Experimental
    Healthy subjects

    Selection of healthy subjects will be performed to ensure age and sex matching. The following procedures will be carried out as part of the research: * Hypercapnic challenge * PET/MRI acquisition with \[18F\]-CPFPX Baseline (0-70 min) Hypercapnic challenge (Breath holding) (70-100 min) Return to equilibrium (100-120 min)

    Procedure: 1 Hypercapnic challenge while participant is awake · Procedure: PET/MRI acquisition

Interventions

  • Procedure1 Hypercapnic challenge while participant is awake

    The healthy patient/subject breathes through the mouth, using a mouthpiece and a nose clip, through a device fitted with a hermetically sealed bag that measures the various parameters of his/her breathing. At the start of the test, the healthy patient/subject breathes ambient air and his or her breathing is measured. Then, after a few minutes, the healthy patient/subject is connected to the bag, breathing in a closed circuit. This causes a gradual increase in carbon dioxide (CO2) in the inspired air. During this time, breathing parameters will be measured and gas exchanges studied with each breath. The test is stopped when the end-tidal carbon dioxide pressure (PetCO2) reaches 60 mm Hg, or in the event of intolerance

  • ProcedurePET/MRI acquisition

    The PET/MRI acquisition will be organized into 3 parts for a total duration of 120 minutes from the injection of the radiotracer 1. Baseline (0-70 min) 2. Respiratory challenge (70-100 min) : Subjects will perform three series of expiratory breath holds (six repeats during each run). A green dot will be shown for 30 seconds, indicating that the patient can still breathe normally for 30 seconds. Then, a yellow dot appears for two seconds, indicating that the patient needs to prepare himself for an expiratory BH that shall start at the end of an expiration, and at the end of the two seconds. Then a red dot appears indicating that the patient must hold his breath while being in full expiration or inspiration. The red dot remains until the patient decides to breath again and push a button to alert us of re-breathing. Screen turns black for 60 seconds before another sequence starts (30 sec. green dot). 3. Return to equilibrium (100-120 min).

06

What researchers measure

Primary outcomes

  1. Comparison of the [18F]-CPFPX BPND in the brainstem structures involved in respiratory regulation under hypercapnic condition in patients with drug-resistant epilepsy with the one of healthy subjects

    All analyses will be performed on Regions of Interest (ROI), defined as brainstem regions with BOLD activation during BH. On the normalized smoothed images, an ANCOVA (analysis of covariance) will be performed, where age, gender and global non-displaceable binding potential (BPND) will be taken into account as covariates of no interest. Statistical parametric maps of the t-statistic (SPM(t)) will be calculated for two contrasts per patient (patient with drug-resistant epilepsy-heathly subjects and heathly subjects-patient with drug-resistant epilepsy) with a threshold of P\<0.001 uncorrected at the voxel level; an extent threshold of 100 voxels (of 2mmx2mmx2mm) will be applied at the cluster level

    Time frame: Emission will be acquired over 90 minutes post-injection

Secondary outcomes

  1. Comparison of the [18F]-CPFPX BPND in the cortical structures involved in respiratory regulation under hypercapnic condition in patients with drug-resistant epilepsy with the one of healthy subjects

    All analyses will be performed on Regions of Interest (ROI), defined as cortical regions with BOLD activation during BH. On the normalized smoothed images, an ANCOVA (analysis of covariance) will be performed, where age, gender and global non-displaceable binding potential (BPND) will be taken into account as covariates of no interest. Statistical parametric maps of the t-statistic (SPM(t)) will be calculated for two contrasts per patient (patient with drug-resistant epilepsy-heathly subjects and heathly subjects-patient with drug-resistant epilepsy) with a threshold of P\<0.001 uncorrected at the voxel level; an extent threshold of 100 voxels (of 2mmx2mmx2mm) will be applied at the cluster level

    Time frame: Emission will be acquired over 90 minutes post-injection

  2. Evaluating the relation between [18F]-CPFPX BPND in the brainstem structures involved in respiratory regulation under hypercapnic condition and the HCVR slope in patients with drug-resistant epilepsy and in healthy subjects

    HCVR measures the increase in minute ventilation (VE) induced by an increase of PETCO2. The HCVR slope, expressed in L/min/mmHg, will be calculated from the linear regression of VE and PETCO2

    Time frame: Emission will be acquired over 90 minutes post-injection

  3. Comparison of the HCVR slope in patients with drug-resistant epilepsy and in heathly subjects

    HCVR measures the increase in minute ventilation (VE) induced by an increase of PETCO2. The HCVR slope, expressed in L/min/mmHg, will be calculated from the linear regression of VE and PETCO2

    Time frame: will be measured during hypercapnic challenges between Day 15 and Day 60 after inclusion

  4. Evaluating the relation between the HCVR slope and the pattern of BOLD activation during BH in patients with drug-resistant epilepsy and in heathly subjects

    Relation between the HCVR slope and mean % change of the BOLD signal in the regions of Interest (ROI), defined as brainstem or cortical regions with BOLD activation during BH.

    Time frame: will be measured during fMRI acquisition (30 minutes)

  5. Comparing brainstem regional volumes on MRI of patients with drug-resistant epilepsy with the one of healthy subjects

    Gray and white matter volumes will be combined to estimate total brain volume for each subject, which will be used as a covariate in subsequent statistical modelling. Two-sample t tests will used for group comparisons in SPM (patients versus healthy subjects), with age, sex, and total brain volume as covariates. Reported P-values will be family-wise error rate (FWER)-corrected (largest cluster at P \< .05). Analysis of relation between VBM and HCVR slope will used Pearson's correlation with age, sex, and total brain volume as covariates. Reported P-values will be family-wise error rate (FWER)-corrected (largest cluster at P \< .05).

    Time frame: Will ne measured during structural MRI protocol which will include 10 minutes of anatomical imaging

  6. Evaluating the relation between the brainstem regional volumes on MRI and the HCVR slope in patients with drug-resistant epilepsy and in heathly subjects

    Analysis of relation between VBM and HCVR slope will use Pearson's correlation with age, sex, and total brain volume as covariates. Reported P-values will be family-wise error rate (FWER)-corrected (largest cluster at P \< .05).

    Time frame: Will be measured during structural MRI protocol which will include 10 minutes of anatomical imaging

  7. Evaluating the relation between mean daily intake of caffeine (mg/day) and the [18F]-CPFPX BPND in the brainstem and cortical structures

    All analyses will be performed on Regions of Interest (ROI), defined as brainstem and cortical regions with BOLD activation during BH. Pearson's correlation with age, sex, and global non-displaceable binding potential (BPND) as covariates

    Time frame: Emission will be acquired over 90 minutes post-injection

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 24 months is below that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start Aug 2026 → Oct 2026, primary completion Aug 2028 → Oct 2028 and completion Oct 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Nov 25, 2025
StartActual
Oct 1, 2026was Aug 2026
Primary completionEst.
Oct 1, 2028was Aug 2028
CompletionEst.
Dec 1, 2028was Oct 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
Hospices Civils de Lyon is now Recruiting
Oct 7, 2026
Start date
Aug 7, 2026→Oct 1, 2026 (actual)
Oct 7, 2026
Primary completion
Aug 7, 2028→Oct 1, 2028
Oct 7, 2026
Study completion
Oct 7, 2028→Dec 1, 2028
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Not yet recruiting→Recruiting
    Hospices Civils de Lyon is now Recruiting
    Start date Aug 7, 2026→Oct 1, 2026 (now actual)
    Primary completion Aug 7, 2028→Oct 1, 2028
    Study completion Oct 7, 2028→Dec 1, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07249034
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Oct 1, 2026
Primary completion
Oct 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Sylvain RHEIMS, PUPH
Contact
sylvain.rheims@chu-lyon.fr
+33472357106
Mathilde LECLERCQ, CP
Contact
Mathilde.leclercq@chu-lyon.fr
+33472355838
Sylvain RHEIMS, PUPH
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion